Vadivelan Ramachandran, Punitha Nanjundan, Triveni Jasti, Manogaran Elumalai
Vadivelan Ramachandran1*, Punitha Nanjundan1, Triveni Jasti1, Manogaran Elumalai2
1Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris Tamilnadu, India-643001.
2Department of Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, UCSI University (South Wing), Cheras, Kuala Lumpur, - 56000, Malaysia.
Volume - 14,
Issue - 7,
Year - 2021
The drug of choice in the treatment of postmenopausal osteoporosis is alendronate. Antidepressive agents are currently used in combination with alendronate to protect against depression and may affect the condition of osteoporosis. The aim is to study the comparative effects of venlafaxine and alendronate on biochemical, bone mechanical and anti-inflammatory properties in osteoporotic induced rats. 36 female Wistar albino rats were included (6 rats/group). Treated groups were ovariectomized bilaterally to induce osteoporosis. Rats were treated orally with alendronate (3mg/kg/day) and venlafaxine (20mg/kg/day) and combined alendronate and venlafaxine for 28 days. Body weight, serum alkaline phosphates, serum calcium, three point bending test, bone mineral mass and inflammatory cytokines The induction of osteoporosis showed significant elevated serum alkaline phosphatase, decreased serum calcium, body weight, bone mineral mass and inflammatory cytokines. Venlafaxine treatment did not ameliorate the changes in tested parameters, where at end of the experiment alendronate has significant improved with serum alkaline phosphatase, serum calcium, bone mineral mass, bone mineral density. The improvement was not affected by combining venlafaxine with alendronate whereas the venlafaxine treatment alone caused a significant deterioration of tested parameters. Venlafaxine is an anti-depressive agent that inhibits brain serotonin which leads to decrease in bone formation. Hence, from the above findings the combination of alendronate and venlafaxine showed worsen the condition of osteoporosis rats.
Cite this article:
Vadivelan Ramachandran, Punitha Nanjundan, Triveni Jasti, Manogaran Elumalai. Comparative effects of Venlafaxine and Alendronate on Biochemical, Bone mechanical and Anti-inflammatory properties in ovariectomized rats. Research Journal of Pharmacy and Technology. 2021; 14(7):3553-8. doi: 10.52711/0974-360X.2021.00615
Vadivelan Ramachandran, Punitha Nanjundan, Triveni Jasti, Manogaran Elumalai. Comparative effects of Venlafaxine and Alendronate on Biochemical, Bone mechanical and Anti-inflammatory properties in ovariectomized rats. Research Journal of Pharmacy and Technology. 2021; 14(7):3553-8. doi: 10.52711/0974-360X.2021.00615 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-7-12
1. Wright NC, Looker AC, Saag KG, Curtis JR, Deizell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck and lumbar spine. Journal of Bone and Mineral Research.2014; 29(11): 2520-62526.
2. Akkawi I, Zmerly H. Osteoporosis: Current concepts. Joints. 2018; 2(2): 122-1227.
3. Kanis JA, Johansson H, Oden A, Cooper C, McCloskey EV. Epidemiology and quality of life working group of IOF. Worldwide uptake of FRAX. Archives of Osteoporosis. 2014; 9: 166.
4. Curtis EM, Moon RJ, Dennison EM, Harvey NC, Cooper C. Recent advances in the pathogenesis and treatment of osteoporosis. Clinical Medicine (London). 2015; 15 (Suppl 6): s92-6.
5. Ramirez J, Nieto-González JC, Rodríguez RC, Castaneda S, Carmona L. Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: A systematic review and meta-analysis. Seminars in Arthritis Rheumatism. 2018; 48(1): 44-52.
6. Mayo Clinic. USA. Osteoporosis, http://https: //www.mayoclinic.org/ diseases- conditions/osteoporosis/ symptoms-causes/syc-20351968; 2019 [assessed 14 March 2019].
7. Mollard E, Bilek L, Waltman N. Emerging evidence on the link between depressive symptoms and bone loss in postmenopausal women. International Journal of Women’s Health. 2017; 28; 10:1-9.
8. Qiu L, Yang Q, Sun N, Li D, Zhao Y, Li X et al. Association between depression and the risk for fracture: a meta-analysis and systematic review. BMC Psychiatry.2018; 18(1): 336.
9. Schweiger J, Schweiger U, Hüppe M, Kahl KG, Greggersen W, Chara K, et al. The use of antidepressive agents and bone mineral density in women: a meta-analysis. International Journal of Environmental Research and Public Health. 2018; 15(7): 1373.
10. Robert A Turner. Screening methods in pharmacology. 1st ed. London. Academic Press, 1971.
11. Osman AS, Dina A Labib A, Abeer I, Omar. Do acid suppressive drugs (pantoprazole and ranitidine) attenuate the protective effect of alendronate in estrogen-deficient osteoporotic rats? The Egyptian Rheumatologist. 2018; 40(2): 99-106.
12. Ho HY, Wu JB, Lin WC. Flemingia macrophylla extract ameliorates experimental osteoporosis in ovariectomized rats. Evidence-Based Complementary and Alternative Medicine. 2011: 1-9.
13. Khan S, Dwivedi C, Parmar V, Srinivasan KK, Shirwaikar A. Methanol extract of dried exudate of Commiphora mukul prevents bone resorption in ovariectomized rats. Pharmaceutical Biology. 2012; 50(10): 1330-1336.
14. Pytlik M, Cegieła U, Folwarczna J, Nowińska B. Proton pump (H+/K+-ATPase) inhibitors weaken the protective effect of alendronate on bone mechanical properties in estrogen-deficient rats. Pharmacological Reports.2012; 64(3): 625-634.
15. Lu Y, He B, Zhang X, Yang R, Li S, Song B et al. Osteoprotective effect of geraniin against ovariectomy-induced bone loss in rats. Bioorganic and Medicinal Chemistry Letters. 2015; 25(3): 673-679.
16. Zeng GF, Zhang ZY, Lu L, Xiao DQ, Xiong CX, Zhao YX et al. Protective effects of Polygonatum sibiricum polysaccharide on ovariectomy-induced bone loss in rats. Journal of Ethno Pharmacology. 2011; 136(1): 224-229.
17. Xu T, Jin H, Lao Y, Wang P, Zhang S, Ruan H, et al. Administration of erythropoietin prevents bone loss in osteonecrosis of the femoral head in mice. Bioorganic and Medicinal Chemistry Letters. 2017; 16(6): 8755-8762.
18. Shukla P. Mansoori MN. Kakaji M, Shukla M, Gupta SK, Singh D. Interleukin 27 (IL-27) alleviates bone loss in estrogen-deficient conditions by induction of early growth response-2 gene. Journal of Biological Chemistry. 2017; 292(11): 4686-4699.
19. Chen B, Li GF, Shen Y, Huang X, Xu YJ. Reducing iron accumulation: a potential approach for the prevention and treatment of postmenopausal osteoporosis. Experimental and Therapeutic Medicine. 2015; 10(1): 7-11.
20. Sakat BT, Sakhare RB, Suryvanshi UC, Kore PS, Mohite SK, Magdum CS. Osteoporosis: The Brittle Bone. Asian Journal of Pharmaceutical Research. 2018; 8(1): 39-43.
21. Lecart MP, Reginster JY. Current options for the management of postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy. 2011; 12(16): 2533-52.
22. Radhakrishna B, Ashok M, PL H, Veera JM, Shivalinge GK. Current and Future Trends of Drugs Used in Osteoporosis. Research Journal of Pharmacology and Pharmacodynamics. 2011; 3(6): 329-33.
23. Chitra V, Ali MA. Animal Models for Osteoporosis-A Review. Research Journal of Pharmacy and Technology. 2020; 13(3): 1543-8.
24. Alkhamees OA, Al-Roujayee AS, Abuohashish MH, Ahmed MM. Anti-osteoporotic effects of an antidepressant tianeptine on ovariectomized rats. Biomedicine and Pharmacotherapy.2017; 87: 575-582.
25. Yoon KH, Cho DC, Yu SH, Kim KT, Jeon Y, Sung JK. The change of bone metabolism in ovariectomized rats: analyses of micro CT scan and biochemical markers of bone turnover. Journal of Korean Neurosurgical Society. 2012; 51(6): 323-7.
26. Shetty S, Kapoor N, Bondu JD, Thomas N, Paul TV. Bone turnover markers: Emerging tool in the management of osteoporosis. Indian Journal of Endocrinology and Metabolism. 2016; 20(6): 846-852.
27. Henriksen K, Christiansen C, Karsdal MA. Role of biochemical markers in the management of osteoporosis. Climacteric.2015; 18(2): 10-8.
28. Mukaiyama K, Kamimura M, Uchiyama S, Ikegami S, Nakamura Y, Kato H. Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover. Aging Clinical and Experimental Research. 2015; 27(4): 413-8.
29. Grassi F, Tell, G, Robbie-Ryan, M, Gao, Y, Terauchi, M, Yang, X.et al. Oxidative stress causes bone loss in estrogen-deficient mice through enhanced bone marrow dendritic cell activation. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(38): 15087-92.
30. Orsal E, Halici Z, Bayir, Y, Cadirci E, Bilen H, Ferah, I. et al. The role of carnitine on ovariectomy and inflammation-induced osteoporosis in rats. Experimental Biology and Medicine.2013; 238(12): 1406-12.
31. Gupta S, Shaikh AM, Mohanty B, Chaudhari P, Parab PB, Apte KG. Evaluation of Antiosteoporotic potential of Sesbania grandiflora Linn. aqueous fraction in Ovariectomized Rats. Research Journal of Pharmacy and Technology. 2020; 13(4): 1806-14.